Current Reports (8-K / 6-K)

Chair Rick Haythornthwaite purchased 2,132 shares, representing the largest transaction among the reporting directors.

Eight independent non-executive directors purchased shares ranging from 198 to 576 shares each.

All share purchases were executed at a price of £5.7700 per share on the London Stock Exchange.

The transactions were conducted in accordance with the Company's Chairman and Non-executive Director shareholding policy.

Chair Rick Haythornthwaite purchased 2,132 shares, representing the largest transaction among the reporting directors.

Eight independent non-executive directors purchased shares ranging from 198 to 576 shares each.

All share purchases were executed at a price of £5.7700 per share on the London Stock Exchange.

The transactions were conducted in accordance with the Company's Chairman and Non-executive Director shareholding policy.

Rennova Health, Inc. — controlled by FOXO’s CEO — holds ~97.59% of voting rights as of March 20, 2026, enabling unilateral approval of corporate actions.

The Majority Stockholder approved a 150% increase in authorized Class A Common Stock, from 10B to 25B shares, via written consent without a shareholder meeting.

The Board fixed March 20, 2026 as the record date for determining stockholders entitled to receive the Schedule 14C Information Statement.

The Authorized Increase will become effective 20 days after mailing of the definitive Schedule 14C, which follows the April 1, 2026 filing of the preliminary version (PRE 14C).

CWCAM assumed general special servicing responsibilities for BANK 2018-BNK15 effective April 2, 2026, replacing LNR Partners.

CWCAM’s role excludes servicing of Non-Serviced Mortgage Loans and NCB Mortgage Loans per the Pooling and Servicing Agreement.

As of December 31, 2025, CWCAM served as special servicer for 330 domestic CMBS pools with $194.7 billion unpaid balance and 9,300 loans.

Two pending legal claims against CWCAM in the CWCapital Cobalt Vr Ltd. litigation were dismissed on January 13, 2026; CWCAM was fully dismissed from the action on January 22, 2026.

A separate lawsuit filed January 13, 2025 (ROC Debt Strategies II v. CWCAM) was dismissed with prejudice on January 22, 2026, following a business resolution.

Sold 59 shares of Series D Preferred Stock at $1,000 each for $59,000 aggregate, plus 6 commitment shares.

Issued warrant for 243,750,000 common shares at $0.000161 exercise price, expiring March 26, 2031.

Series D Preferred has $1,200 stated value and 8% annual dividend paid quarterly in cash or shares.

Potential to sell up to 13 additional Series D shares at GHS discretion, subject to equity conditions.

Sale relied on Section 4(a)(2) and Rule 506, to accredited investor GHS without registration.

Warrants include full-ratchet anti-dilution and 4.99% beneficial ownership limit.

Separate trading of Class A Ordinary Shares and Warrants commences April 6, 2026.

Each Unit consists of one Class A Ordinary Share and one-quarter of one Warrant.

Whole Warrants trade only; no fractional Warrants will be issued upon separation.

Unseparated Units continue trading under symbol 'HACQU' on the Nasdaq.

Separated Class A Ordinary Shares and Warrants will trade under symbols 'HACQ' and 'HACQW'.

David Lindberg received 1,034,617 ordinary shares valued at approximately £11.01 million, granted to buy out forfeited awards from his previous employer.

Of the total award, 128,664 shares vested immediately, with 60,473 shares sold to cover tax and social security liabilities, resulting in 68,191 net shares.

The remaining 905,953 shares are deferred awards vesting in annual tranches from March 2027 through March 2032, subject to 12-month retention periods.

The awards were priced at £10.646 per share based on the closing price on the London Stock Exchange on Lindberg's start date of December 8, 2025.

David Lindberg received 1,034,617 ordinary shares valued at approximately £11.01 million, granted to buy out forfeited awards from his previous employer.

Of the total award, 128,664 shares vested immediately, with 60,473 shares sold to cover tax and social security liabilities, resulting in 68,191 net shares.

The remaining 905,953 shares are deferred awards vesting in annual tranches from March 2027 through March 2032, subject to 12-month retention periods.

The awards were priced at £10.646 per share based on the closing price on the London Stock Exchange on Lindberg's start date of December 8, 2025.

Cameco's 2025 Modern Slavery Report covers the financial year ended December 31, 2025, as required by the Fighting Against Forced Labour and Child Labour in Supply Chains Act.

The company considers modern slavery risk low in its controlled operations due to locations in Canada, the U.S., and Australia with established labor laws.

In 2025, Cameco sourced inputs from approximately 2,061 suppliers globally with total annual spend of approximately $1.264 billion for Canadian operations.

Approximately 91% of Cameco's procurement spend for Canadian operations was with suppliers located in Canada, with 99% in Canada or the United States.

Cameco purchased 9.6 million pounds of uranium from 11 suppliers in 2025, with JV Inkai in Kazakhstan providing approximately 47% of purchased uranium.

The company updated its Supplier Code of Conduct and Ethics in 2024 to explicitly prohibit suppliers from engaging in forced labor, compulsory labor, or child labor.

Form 6-K filed with Exhibit 99.1 (d711806dex991.pdf) on 2026-04-02.

Document items listed as N/A.

Content primarily consists of uuencoded PDF data with no discernible textual facts.

The annual meeting will be held virtually on May 7, 2026, with shareholders of record as of March 9, 2026, eligible to vote.

Shareholders will vote on electing nine directors, reappointing KPMG LLP as auditor, and an advisory resolution on executive compensation.

The company reported 435,532,978 common shares outstanding as of March 9, 2026, and 435,457,978 as of December 31, 2025.

Director Daniel Camus is not standing for re-election after reaching the 15-year term limit, with nine other nominees proposed for election.

The company has adopted notice-and-access for delivering meeting materials electronically to reduce printing and mailing costs.

The Federal Home Loan Bank of Indianapolis will assume primary obligation for $15 million in bonds on April 7, 2026.

The bonds carry a fixed 4.000% coupon rate and mature on April 7, 2028.

The bonds are callable at the FHLBank's discretion on specified dates starting January 7, 2027.

Consolidated obligations are joint obligations of all FHLBanks and are not guaranteed by the U.S. government.

The reported $15 million par amount may differ from financial statement amounts due to discounts or premiums.

The Company declared a distribution for March 2026, with net amounts of $0.16000 per share for Class I and $0.14602 per share for Class S.

The distribution is payable to stockholders of record as of the open of business on March 31, 2026.

Payment will be made on or about April 9, 2026.

Distributions will be paid in cash or reinvested for participants in the Company's distribution reinvestment plan.

As of March 30, 2026, the Company had no shares of Class D common stock outstanding.

FHLBank issued $2.0 billion in consolidated obligation bonds across two separate CUSIPs.

Both issuances are Non-Callable Variable Single Index Floater bonds with short-term maturities.

Obligations are joint and several among the eleven Federal Home Loan Banks but not guaranteed by the U.S. government.

The bonds were traded on March 30, 2026, and settled on April 1, 2026.

Granted Awards for 2,119,724 ordinary shares of US$0.50 each at GBP 0 purchase price on 31 March 2026.

Vesting over three years: 33% on first and second anniversaries, 34% on third; up to five years for Material Risk Takers.

Awards subject to 12-month post-vesting retention; certain tied to project completion or buy-out mirroring prior awards.

Plan has 1,108,295,038 shares available under 10% limit and 355,511,014 under 5% limit.

No performance targets on Awards; clawback per regulatory obligations and prior forfeited awards.

Granted Awards for 2,119,724 ordinary shares of US$0.50 each at GBP 0 purchase price on 31 March 2026.

Vesting over three years: 33% on first and second anniversaries, 34% on third; up to five years for Material Risk Takers.

Awards subject to 12-month post-vesting retention; certain tied to project completion or buy-out mirroring prior awards.

Plan has 1,108,295,038 shares available under 10% limit and 355,511,014 under 5% limit.

No performance targets on Awards; clawback per regulatory obligations and prior forfeited awards.

FHLBank committed to issue $5M fixed-rate bond (5.75% coupon) maturing 4/13/2046 with optional principal redemption.

FHLBank committed to issue three variable Single Index Floater notes totaling $1.9B maturing between 8/4/2026 and 10/1/2026, all non-callable.

Consolidated obligations are joint and several liabilities of the eleven Federal Home Loan Banks, backed solely by their financial resources.

Schedule A excludes discount notes with maturity ≤1 year issued in ordinary course and does not reflect total outstanding obligations.

Principal amounts reported at par; may differ from GAAP financial statements due to discounts/premiums.

FHLBank may change reporting method for consolidated obligations at any time.

Account targets 75-85% net assets in direct real estate or related investments, holding 20.1% via joint ventures as of Dec 31, 2025.

Loan-to-value ratio was 18.4% as of Dec 31, 2025, below 30% guideline with 25% target.

Liquid fixed income investments targeted at 15-25% of net assets to support liquidity.

No liquid real estate-related securities held as of Dec 31, 2025.

Credit facilities include $1.4B revolving line; recent $700M note issuance in Oct 2025 with Series D and E notes.

FAQ covers investment strategy, risks, performance indicators, and liquidity guarantees.

Scrip reference price set at US$13.834482 per new ordinary share for the 2025 second interim dividend.

Dividend amount is 18.89 US cents per ordinary share, payable under the Evergreen Scrip Dividend Scheme.

Minimum shareholding requirement of 74 ordinary shares on record date (27 March 2026) to participate in scrip alternative.

Scrip reference price calculated as five-day LSE average middle-market price converted to USD using WMR spot rate on 1 April 2026.

Scrip reference price set at US$13.834482 per new ordinary share for the 2025 second interim dividend.

Dividend amount is 18.89 US cents per ordinary share, payable under the Evergreen Scrip Dividend Scheme.

Minimum shareholding requirement of 74 ordinary shares on record date (27 March 2026) to participate in scrip alternative.

Scrip reference price calculated as five-day LSE average middle-market price converted to USD using WMR spot rate on 1 April 2026.

Bank committed to two consolidated obligation bonds totaling $25 million par amount.

First bond: $10M, 4.730% fixed rate, matures 4/3/2036, Bermudan call from 4/3/2028.

Second bond: $15M, 4.000% fixed rate, matures 10/6/2028, European call on 10/6/2026.

Bonds are joint obligations of 11 FHLBanks, backed solely by FHLBanks' resources, not U.S. government.

Schedule A excludes short-term discount notes and derivative instruments.

Bank has not judged materiality of these obligations.

Company updated corporate presentation for investor meetings.

Presentation filed as Exhibit 99.1 to this 8-K.

Executive Directors Deepak Nath and John Rogers received deferred share bonus awards on April 1, 2026, with 83,494 and 48,071 shares respectively, vesting on March 15, 2029.

Performance share awards were granted to 12 PDMRs under the Global Share Plan 2020 on April 1, 2026, with vesting subject to performance conditions measured from January 2026 to December 2028.

Restricted share awards were granted to 12 PDMRs under the Restricted Share Plan 2024 on April 1, 2026, vesting in equal annual tranches over three years, with additional conditions for the CEO and CFO.

All awards were calculated using a share price of £12.744, based on the ten-day average following the company's full-year 2025 results announcement on March 2, 2026.

Participants in all plans will receive additional shares equivalent to dividends payable on vested shares during the respective vesting periods.

Executive Directors Deepak Nath and John Rogers received deferred share bonus awards on April 1, 2026, with 83,494 and 48,071 shares respectively, vesting on March 15, 2029.

Performance share awards were granted to 12 PDMRs under the Global Share Plan 2020 on April 1, 2026, with vesting subject to performance conditions measured from January 2026 to December 2028.

Restricted share awards were granted to 12 PDMRs under the Restricted Share Plan 2024 on April 1, 2026, vesting in equal annual tranches over three years, with additional conditions for the CEO and CFO.

All awards were calculated using a share price of £12.744, based on the ten-day average following the company's full-year 2025 results announcement on March 2, 2026.

Participants in all plans will receive additional shares equivalent to dividends payable on vested shares during the respective vesting periods.

Phase 3 trial (N=90) missed primary endpoint: no statistically significant HAM-D17 reduction vs placebo at hour 60.

Post hoc analysis (n=54 with psychiatric history) showed statistically significant HAM-D17 reductions vs placebo from hour 12 through day 30.

LPCN 1154 well tolerated with no AEs >5%, no SAEs, no discontinuations, supporting outpatient use.

Applied for FDA breakthrough therapy and fast track designations based on post hoc results.

Plans to evaluate options including continued development, partnerships, or strategic transactions while preserving capital.

Annual general meeting scheduled for May 6, 2026 at 3:00 pm Mountain Time, virtual-only via specified link.

Formal business includes receiving 2025 financials, fixing 8 directors, electing directors, appointing Deloitte LLP as auditors, and advisory vote on executive compensation.

152,599,504 common shares outstanding as of March 18, 2026, traded as VET on TSX and NYSE.

2025 highlights include 46% production per share growth, 30% unit cost reduction, and portfolio repositioning via Westbrick acquisition and divestitures.

Announced 2026 budget with over 40% production per share increase versus 2024 and 30% capital efficiency improvement.

Circular mailed April 2, 2026 using notice-and-access model.

Cre8's subsidiary acquired 100% of Upperhand Investment Limited, a holding company with a Japanese operating subsidiary, for US$200,000 in cash.

The acquisition aims to grant capabilities for cross-border IPOs and dual listings in Japan and address jurisdiction-specific regulatory requirements.

The purchase price was paid in full on March 17, 2026, and title to the shares was transferred on April 1, 2026.

The acquisition is expected to realize operational efficiencies through integration of resources across logistics, technology, and infrastructure.

Issued 739,840 ordinary shares valued at $500,000 for M&A consulting on Chaokun acquisition.

Issued 190,245 ordinary shares valued at $90,000 for 12-month investor relations services.

Issued 697,564 ordinary shares valued at $330,000 for 12-month financial advisory services.

Total shares issued: 1,627,649 on February 26, 2026, to unaffiliated third-party advisors.

Post-issuance ordinary shares outstanding: 10,248,337.

Shares issued under Section 4(a)(2) or Regulation D exemption, unregistered under Securities Act.

EMERALD-3 Phase III trial met its primary endpoint of progression-free survival (PFS) with statistical significance in embolisation-eligible unresectable hepatocellular carcinoma (HCC).

The combination of Imfinzi, Imjudo, lenvatinib, and TACE showed a trend toward improved overall survival (OS) versus TACE alone at interim analysis.

The STRIDE regimen plus TACE arm also showed strong trends toward improved PFS and OS, although not formally tested at this time.

Safety profiles for the combinations were consistent with the known profiles of the medicines, with no new safety findings identified.

AstraZeneca is discussing the positive data with global regulatory authorities while awaiting final results for key secondary endpoints.

EMERALD-3 Phase III trial met its primary endpoint of progression-free survival (PFS) with statistical significance in embolisation-eligible unresectable hepatocellular carcinoma (HCC).

The combination of Imfinzi, Imjudo, lenvatinib, and TACE showed a trend toward improved overall survival (OS) versus TACE alone at interim analysis.

The STRIDE regimen plus TACE arm also showed strong trends toward improved PFS and OS, although not formally tested at this time.

Safety profiles for the combinations were consistent with the known profiles of the medicines, with no new safety findings identified.

AstraZeneca is discussing the positive data with global regulatory authorities while awaiting final results for key secondary endpoints.

Signed $60.0 million revolving credit facility with a leading European Financial Institution.

Facility tenor of five years with interest at Term SOFR plus margin.

Secured by first priority mortgage over four Company vessels.

Net proceeds for general corporate purposes.

Company operates two LPG carriers and one MR tanker.

Michael K. Kneller, Vice President, General Counsel and Secretary since 2005, resigns May 8, 2026 to join Scopelitis, Garvin, Light, Hanson & Feary, P.C.

Vallie S. Dugas, current Vice President and Assistant General Counsel, named Interim Vice President, General Counsel and Secretary effective May 8, 2026.

Departure announced April 2, 2026.

Kneller's exit removes long-tenured legal leadership.

Interim appointment ensures continuity in key legal oversight role.

Blue Bird acquired the remaining 50% interest in Micro Bird, becoming the sole owner of the joint venture enterprise.

The aggregate purchase price was $201,787,193, paid roughly 30% in cash ($63.0 million) and 70% in stock ($138.8 million).

The stock consideration involves 2,702,180 shares, issued as exchangeable shares subject to a six-month lock-up with staggered release through 2029.

Steve Girardin was appointed as a Class III Director effective March 30, 2026, with a term expiring at the 2029 annual stockholder meeting.

A Special Voting Preferred Stock was created to provide voting rights to holders of the Exchangeable Shares equivalent to common stockholders.

The acquisition strengthens Blue Bird's portfolio with Buy America-compliant shuttle buses and Type A school buses.

John Achille promoted to President and COO effective immediately on April 1, 2026.

Achille retains oversight of Installation Services and Specialty Distribution day-to-day operations.

New responsibilities include Supply Chain organization and all growth initiatives such as M&A.

Achille continues reporting to CEO Robert Buck.

Promotion signals internal leadership continuity and focus on profitable growth.

Achille joined TopBuild in 2021 via acquisition and has held progressive leadership roles.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

F-Series sold 159,901 trucks — America’s No. 1 truck for Q1 — with March volume at 62,238, the quarter’s highest; reflects continued demand despite tight dealer supply.

Large SUV sales (Bronco, Explorer, Expedition) rose 17.9% — best Q1 start since 2002 — lifting retail share amid Escape and Corsair sunsetting.

Explorer sales surged 29.7% to 61,387 units, extending its lead as America’s top three-row SUV; Expedition up 30.2% to 17,554 units.

Ford Pro paid software subscriptions grew ~29% to >865,000, and BlueCruise surpassed 10.1 million cumulative hands-free driving hours.

Commercial vehicle leadership continued: Ford ranked No. 1 in U.S. Class 1–7 trucks/vans in January, with share up 1 percentage point YoY.

Lincoln Aviator sales jumped 31.4% to 6,266 units — record Q1 — while Navigator rose 6.5% to 4,322 units.

Nasdaq issued a Staff Delisting Determination Letter on March 27, 2026, citing the low bid price rule.

The closing bid price remained at $0.10 or below for 10 consecutive trading days through March 25, 2026.

Trading in the Company's ADSs will be suspended at the opening of business on April 6, 2026.

The Company intends to appeal the delisting determination to the Nasdaq Hearings Panel.

A hearing request will not stay the trading suspension scheduled for April 6, 2026.

Oncotelic and TechForce executed a binding Joint Development, Manufacturing, and Licensing Agreement effective March 31, 2026 — establishes formal collaboration framework with defined IP ownership and development obligations.

The integrated Product combines TechForce’s robotic hardware with Oncotelic’s proprietary PDAOAI Platform — creates a novel AI-robotics solution targeted specifically at GMP-regulated pharmaceutical manufacturing.

All AI-related foreground IP, including PDAOAI improvements, is owned exclusively by Oncotelic — strengthens Oncotelic’s control over core AI assets and future commercialization rights.

Data generated through Product operation, deployment, and testing is owned exclusively by Oncotelic — enhances data sovereignty and supports regulatory submissions and product validation.

Commercial terms (revenue sharing, royalties, profit-sharing) are deferred to a future Commercialization and Licensing Agreement — no revenue-generating activities may commence without mutual written consent.

TechForce is restricted for 12 months post-termination from licensing jointly developed IP to third parties in pharmaceutical/biopharmaceutical manufacturing — provides Oncotelic with competitive protection during transition.

Nasdaq determined the Company complies with continued listing standards, closing the matter.

Compliance follows the filing of the Annual Report on Form 10-K on March 31, 2026.

The Form 10-K evidenced stockholders' equity of $3,953,682.

The Company had previously received a non-compliance notice from Nasdaq on December 1, 2025.

The Group assessed the FCA's final motor finance redress rules and concluded no current adjustment to its provision is required.

Uncertainties persist around customer response rates, operational implementation costs, and potential legal proceedings.

The ultimate financial impact may differ depending on actions by customers, regulators, or courts, including complaints and litigation.

An update on the matter will be provided with the Group's first quarter results at the end of April 2026.

The Group assessed the FCA's final motor finance redress rules and concluded no current adjustment to its provision is required.

Uncertainties persist around customer response rates, operational implementation costs, and potential legal proceedings.

The ultimate financial impact may differ depending on actions by customers, regulators, or courts, including complaints and litigation.

An update on the matter will be provided with the Group's first quarter results at the end of April 2026.

The Group assessed the FCA's final motor finance redress rules and concluded no current adjustment to its provision is required.

Uncertainties persist around customer response rates, operational implementation costs, and potential legal proceedings.

The ultimate financial impact may differ depending on actions by customers, regulators, or courts, including complaints and litigation.

An update on the matter will be provided with the Group's first quarter results at the end of April 2026.

Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire as directors effective May 21, 2026.

Retirements not due to any dispute or disagreement with the Company or Board.

Board nominates David P. King for election at 2026 annual meeting of stockholders.

David P. King is former Executive Chairman and CEO of Laboratory Corporation of America Holdings.

King currently serves as director and chair of Privia Health and AmSurg Corporation, and director of Smith & Nephew.

Produced 408,386 vehicles in Q1 2026, including 394,611 Model 3/Y and 13,775 other models.

Delivered 358,023 vehicles in Q1 2026, with 341,893 Model 3/Y and 16,130 other models.

Deployed 8.8 GWh of energy storage products in Q1 2026.

Financial results to be released April 22, 2026 after market close.

Q&A webcast scheduled for April 22, 2026 at 4:30 p.m. CT on ir.tesla.com.

Deliveries and deployments not indicators of quarterly financial results.

Shareholders approved re-designating 20,000,000 shares as Class A Ordinary Shares, resulting in 518,911,230 Class A Ordinary Shares and 81,088,770 Class B Ordinary Shares.

The company's memorandum and articles of association were amended and restated to incorporate the approved resolutions.

The 2026 Share Scheme was adopted, including approval of grants of 1,400,000 RSUs to Dr. Jun Peng and 600,000 RSUs to Dr. Tiancheng Lou.

Directors were granted a general mandate to issue, allot, and deal with additional Class A ordinary shares and/or ADSs not exceeding 20% of total issued shares.

Directors were granted a general mandate to repurchase shares and/or ADSs not exceeding 10% of total issued shares.

Giannis Antetokounmpo joined as a Global Partner and shareholder of IM8, receiving equity instead of cash compensation, signaling strong alignment with Prenetics' long-term vision.

IM8 reached $100M annualized recurring revenue within 11 months of launch (December 2024), a record pace for the supplement industry.

IM8 is projected to generate $180M–$200M in full-year 2026 revenue and has delivered over 22 million servings to 750,000+ customers across 31 countries.

Prenetics reported approximately $160M in adjusted liquidity as of March 1, 2026, with zero debt and adjusted EBITDA profitability targeted by Q4 2027.

The partnership expands IM8’s reach to Giannis’s 35M+ social followers and leverages NBA broadcast coverage in 215 countries to accelerate international market activation.

Giannis Antetokounmpo joined as a Global Partner and shareholder of IM8, receiving equity instead of cash compensation, signaling strong alignment with Prenetics' long-term vision.

IM8 reached $100M annualized recurring revenue within 11 months of launch (December 2024), a record pace for the supplement industry.

IM8 is projected to generate $180M–$200M in full-year 2026 revenue and has delivered over 22 million servings to 750,000+ customers across 31 countries.

Prenetics reported approximately $160M in adjusted liquidity as of March 1, 2026, with zero debt and adjusted EBITDA profitability targeted by Q4 2027.

The partnership expands IM8’s reach to Giannis’s 35M+ social followers and leverages NBA broadcast coverage in 215 countries to accelerate international market activation.

Company received Nasdaq non-compliance notice on December 31, 2025, for bid price below $1.00 for 30 consecutive business days.

Implemented reverse stock split effective March 6, 2026, trading on split-adjusted basis from March 9, 2026.

Hearings Panel granted exception period until March 20, 2026, to achieve $1.00 bid price for 10 consecutive business days.

Common stock closed at $7.47 on March 20, 2026, meeting compliance requirement.

Nasdaq confirmed full compliance with all listing requirements on March 31, 2026.

Subject to Mandatory Panel Monitor until March 31, 2027, with potential delisting hearing if non-compliant.